Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
07 juil. 2022 01h30 HE
|
Spexis AG
ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
08 janv. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...